🇺🇸 FDA
Pipeline program

patisiran

001 amendment 02

Phase 1 small_molecule completed

Quick answer

patisiran for Polyneuropathies is a Phase 1 program (small_molecule) at Alnylam Netherlands B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Alnylam Netherlands B.V.
Indication
Polyneuropathies
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials